drugset / Trial / NCT05219669

Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens

NCT05219669

Phase 1 Completed 24 enrolled Opiant Pharmaceuticals Inc
RandomizedCrossoverOpen-labelBasic science

Summary

This study is to compare the pharmacokinetics (how the body absorbs, breaks down and eliminates drug from your body) of nalmefene when given as a single dose intranasally (IN;into the nose), as a single dose in each nostril and as two doses in one nostrils; and to evaluate the safety and tolerability of nalmefene IN.

Timeline

Start
2021-09-01
Primary completion
2021-11-19
Completion
2021-11-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Nalmefene Small molecule 3 mg Intranasal
Subject Nalmefene Small molecule 6 mg Intranasal